PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

NCT01839487 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: PEGPH20
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Dexamethasone
DRUG: Enoxaparin

Sponsor

Halozyme Therapeutics